PATENT CLAIM ANALYSIS

Application Number: 16282540
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-08
Patent Classification: ["506", "009000"]

Abstract:
Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.

Claim (Index 25):
The method of  claim 21 , wherein the tissue sample has a positive TMPRSS2 fusion status.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 99.0
- Lexical Diversity: 1.57143
- Patent Class: 506.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14887605', '15554060', '13752199', '16155220', '13830325']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6172612390869813
- 35 USC 102 Novelty (BERT): 0.566181037454046
- Combined Prediction Score: 0.6121532189236878
- Mean Citation Score: 290.472522
- Max Citation Score: 450.8793
- Similarity Product: 391.4958986942768

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test